NDAINHALATIONAEROSOL, METERED
Approved
Jul 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
SYMBICORT (budesonide and formoterol fumarate dihydrate) by AstraZeneca is corticosteroid hormone receptor agonists [moa]. First approved in 2006.
Drug data last refreshed 1h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYMBICORT is a fixed-dose combination inhaler containing budesonide (a corticosteroid) and formoterol (a long-acting beta-2 agonist) used to treat asthma and COPD. It works by reducing airway inflammation via corticosteroid receptor agonism and bronchodilation through beta-2 adrenergic stimulation. The combination addresses both the inflammatory and obstructive components of chronic respiratory disease.
$2.0BPart D
LOE ApproachingStable
As LOE approaches with $2B in annual spending, the brand faces defensive positioning requiring experienced managers and medical liaisons to protect market share against generic and alternative therapies.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (FORSYYN)
Started Jul 2018
750 enrolled
Chronic Obstructive Pulmonary Disease
A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers Without Charcoal Block
Started Jun 2017
99 enrolled
AsthmaCOPD
Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants
Started Jan 2017
1,714 enrolled
Asthma
Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (TRIVERSYTI)
Started Dec 2016
708 enrolled
COPD (Chronic Obstructive Pulmonary Disease)
A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers
Started Nov 2016
50 enrolled
Study is Being Conducted in Healthy Volunteers
Worked on SYMBICORT at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.